Sanara MedTech, Inc. SMTI

MiMedx reports strong surgical momentum and a transformational acquisition, while navigating a challenging wound care market with early signs of stabilization.

MiMedx Group (NASDAQ:MDXG) said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx’s second-quarter results, which showed sequential improvement in its wound-care busines

Reports Second Quarter Net Sales of $64 Million Reiterates Full Year Financial Outlook on a Standalone Basis Announces Plans to Acquire Sanara MedTech Management to Host Conference Call Today, July 29, 2026, at 4:30 PM ET MARIETTA, Ga., July 29, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2026. Joseph H. Capper, MIMEDX Chief Executive Officer, commented, "During the second quarter,

Transformational Combination Creates a Leading Regenerative Medicine Company Across Numerous Surgical Subspecialties Accelerates MIMEDX’s Strategic Priority to Expand Surgical Footprint, Nearly Doubling Surgical Revenue Immediately Accretive to Revenue Growth, Gross Margin and Adjusted EBITDA Margin Anticipates Over $20 Million in Run-Rate Cost Synergies Conference Call to Discuss Transaction Alongside MIMEDX’s Second Quarter 2026 Operating and Financial Results Today at 4:30pm EDT MARIETTA, Ga.

Sanara MedTech is back in focus as the consensus fair value estimate edges from US$34.00 to about US$34.33 per share, giving investors a refreshed reference point for the stock. That small move lines up with recent analyst commentary that leans constructive on the company’s role in surgical wound and soft tissue management and what that could mean for future execution and valuation work. In the sections ahead, you will see how this evolving narrative fits with updated growth and margin...

Sanara MedTech’s fair value target is held at US$34.00 per share, with no change from the previous US$34.00 estimate. Bullish and bearish analysts are reading that steady target very differently, with some seeing it as a sign of conviction in the updated model and others viewing it as heavily dependent on specific assumptions. As you read on, you will see what is driving these views and how to track the narrative as it develops. Analyst Price Targets don't always capture the full story. Head...

Moby summary of Sanara MedTech Inc.'s Q1 2026 earnings call

Sanara MedTech Inc (SMTI) reports a 19% revenue increase and strategic sales team expansion, despite facing operational challenges.

Sanara MedTech’s fair value target is restated at US$34.00, effectively signaling no movement in the headline price objective. Analysts linking this steady target to their current framework describe it as consistent with the existing model, while differing views highlight both the conviction and the constraints that come with leaving core assumptions untouched. As you read on, you will see how this steady US$34.00 figure fits into a broader, evolving narrative that you can track over...

White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The letter indicated that the first quarter of 2026 was a turnaround period. During this quarter, US military actions against Iran and developments in AI dominated economic discussions. These military interventions created a […]